ATX 0.00% 15.5¢ amplia therapeutics limited

Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-27

  1. 869 Posts.
    lightbulb Created with Sketch. 216
    Interesting reading on the competition - multiple FAK inhibitors in clinical trials. Few phase 1s and 2s. A reminder there's no time to waste here!
 
watchlist Created with Sketch. Add ATX (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.